Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q80510555)
Watch
English
Genitourinary malignancies
scientific article published on 01 January 2003
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
15338763
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338763%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 January 2020
review article
1 reference
stated in
Europe PubMed Central
title
Genitourinary malignancies
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
15338763
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338763%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 January 2020
author
Dror Michaelson
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
15338763
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338763%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 January 2020
author name string
Matthew R Smith
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
15338763
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338763%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 January 2020
publication date
1 January 2003
1 reference
stated in
Europe PubMed Central
PubMed publication ID
15338763
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338763%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 January 2020
published in
Cancer chemotherapy and biological response modifiers
1 reference
stated in
Europe PubMed Central
PubMed publication ID
15338763
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338763%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 January 2020
volume
21
1 reference
stated in
Europe PubMed Central
PubMed publication ID
15338763
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338763%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 January 2020
page(s)
547-564
1 reference
stated in
Europe PubMed Central
PubMed publication ID
15338763
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338763%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 January 2020
cites work
A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Surgery and the reduction of mortality from prostate cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormone refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I clinical and pharmacologic trial of intravenous estramustine phosphate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Weekly high-dose calcitriol and docetaxel in advanced prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Docetaxel and exisulind in hormone-refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Preliminary observations of single-agent docetaxel as neoadjuvant therapy for locally advanced prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anti-tumor effects of toxins targeted to the prostate specific membrane antigen
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Natural history of progression after PSA elevation following radical prostatectomy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Percutaneous radio frequency ablation of small renal tumors: initial results
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Radio-frequency ablation of renal cell carcinoma: early clinical experience
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The von Hippel-Lindau tumor suppressor protein
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
von Hippel-Lindau disease: genetic and clinical observations
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide is an inhibitor of angiogenesis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The treatment of advanced renal cell cancer with high-dose oral thalidomide
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cystectomy for bladder cancer: a contemporary series
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pelvic lymph node dissection can be curative in patients with node positive bladder cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term side effects of treatment for testis cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Second malignancies following pure seminoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single-center study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Diagnosis and monitoring of urological tumors using positron emission tomography
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of gemcitabine in refractory germ cell tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adsorptive voltametry to determine platinum levels in plasma from testicular cancer patients treated with cisplatin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long term effect of Cis-Diamminedichloride platinum (CDDP) on renal function and structure in man
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Resear
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term renal function after treatment for malignant germ-cell tumours
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nontraumatic osteonecrosis after chemotherapy for testicular cancer: a systematic review.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0921-4410%2803%2921026-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0921-4410(03)21026-7
1 reference
stated in
Europe PubMed Central
PubMed publication ID
15338763
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338763%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 January 2020
PubMed publication ID
15338763
1 reference
stated in
Europe PubMed Central
PubMed publication ID
15338763
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15338763%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 January 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
